Intra-Cellular bolsters Caplyta data with another Phase III win [Yahoo! Finance]
Intra-Cellular Therapies Inc. (ITCI)
Last intra-cellular therapies inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intracellulartherapies.com/investor-relations
Company Research
Source: Yahoo! Finance
from a Phase III trial of the therapy for prevention in relapse in schizophrenia patients. The Study 304 (NCT04959032) trial met its primary endpoint of time to relapse during the 26-week double-blind treatment phase, with Caplyta treatment associated with a 63% reduction in the risk of relapse compared to the placebo. Caplyta is Inta-Cellular's only marketed therapy. Last year, the drug generated $462.2m in sales, and the company expects net product sales for Caplyta this year to be between $665m and $685m, as per the company's financials. GlobalData expects therapy sales to maintain an upward trajectory and generate over $3bn in sales by 2030. GlobalData is the parent company of Clinical Trials Arena The multi-centre, parallel-group Phase III study enrolled 228 patients. All participants were treated with 42mg Caplyta in an 18-week open-label period before being randomised to receive either Caplyta or placebo as part of the double-blind treatment phase. The time to relapse w
Show less
Read more
Impact Snapshot
Event Time:
ITCI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ITCI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ITCI alerts
High impacting Intra-Cellular Therapies Inc. news events
Weekly update
A roundup of the hottest topics
ITCI
News
- Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Intra-Cellular Therapies to Participate in Three Upcoming Investor ConferencesGlobeNewswire
- Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI CongressGlobeNewswire
- Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with SchizophreniaGlobeNewswire
- Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at JPMorgan Chase & Co. from $81.00 to $89.00. They now have an "overweight" rating on the stock.MarketBeat
ITCI
Earnings
- 10/30/24 - Miss
ITCI
Sec Filings
- 11/14/24 - Form 4
- 11/12/24 - Form 144
- 11/12/24 - Form SC
- ITCI's page on the SEC website